modernretina

Lynda Charters

Modern Retina’s recent Case-Based Roundtable focused on next-generation treatments for retinal disease that provide advanced care for neovascular age-related macular degeneration (nAMD) and diabetic ...
modernretina

Frank Holz, MD, FEBO, FARVO, highlights new treatment developments at EURETINA

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life. Frank Holz, MD, FEBO, FARVO, a retina specialist from Bonn, Germany, discusses ...
modernretina

Challenges Reported by Young Physicians in Managing Geographic Atrophy and How these Shape Patient Care

A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient ...
modernretina

The Retina TL;DR: Advancing sustained VEGF suppression with EYP-1901 with Jay S. Duker, MD

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and ...
modernretina

Q&A: What is the value of the YOURS program at EURETINA?

Learn how the YOURS Committee empowers young retina specialists through engaging educational initiatives, networking opportunities, and exam preparation resources. Kristina Pfau, MD, FEBO, is a ...
modernretina

Kristina Pfau, MD, FEBO

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.
modernretina

Kristina Pfau, MD, FEBO, discusses her research using high-resolution OCT to examine PXE patients, and more

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee. Kristina Pfau, MD, FEBO, a consultant ...
modernretina

Peter Kaiser, MD, discusses OTX-TKI, a new treatment for wet AMD, introduced by Ocular Therapeutics

Peter Kaiser, MD, from Ocular Therapeutix, introduces OTX-TKI (Axpaxli), a novel tyrosine kinase inhibitor delivered through a proprietary hydrogel platform. This innovative treatment for wet ...
modernretina

Eydenzelt, Celltrion’s biosimilar referencing Eylea, approved by FDA

Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology. Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology. It was also approved by the European ...
modernretina

Fanka Gilevska, MD, PhD

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD.
modernretina

Nadia Waheed, MD, MPH: Transforming retinal disease imaging and clinical trials

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions. Nadia Wahid, MD, a professor of ...
modernretina

Charles Miller, MD, PhD, on DME research and the initiation of the phase 2b/3 BRUNELLO trial

Merck and EyeBio launch a pivotal trial for MK-3000, targeting diabetic macular edema with new treatment options to enhance patient outcomes. On September 4, 2025, Merck and EyeBio announced that the ...